ClinicalTrials.Veeva

Menu
R

Revive Research Institute | Pulmonary Disease - Dr Syed T. Raza

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Eloralintide
LY3841136
HBS-301
tilrekimig
LY3537031
PF-07275315
Astegolimab
Povorcitinib
Brenipatide
Ensifentrine

Parent organization

This site is a part of Revive Research Institute

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

14 of 18 total trials

A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Idiopathic Hypersomnia (IH)

This is a Phase 3, multicenter, randomized, double-blind, parallel-group, placebo-controlled clinical study to assess the efficacy and safety of HBS-...

Enrolling
Idiopathic Hypersomnia
Drug: HBS-301 tablet
Drug: Placebo

This is a Phase 3, multicenter, randomized, double-blind, parallel-group, placebo-controlled clinical study to assess the efficacy and safety of HBS-...

Enrolling
Cataplexy
EDS
Drug: HBS-301
Other: Placebo

The main purpose of this study is to assess if different dose levels of Brenipatide are safe and work the way they are intended to work in participan...

Enrolling
Pulmonary Disease, Chronic Obstructive
Drug: Placebo
Drug: Brenipatide
Locations recently updated

The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with a placebo in participants with obesity or overwei...

Begins enrollment this month
Overweight
Obesity
Drug: Eloralintide
Drug: Placebo

The purpose of the studies is to evaluate the efficacy and safety of eloralintide in participants with moderate-to-severe obstructive sleep apnea and...

Enrolling
Overweight
Sleep Apnea, Obstructive
Drug: Placebo
Drug: Eloralintide

The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo in participants with persistent obesity o...

Enrolling
Overweight
Obesity
Drug: Placebo
Drug: Eloralintide

A Randomized, Double-blind, Placebo-controlled, Multiple Dose-Ranging Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic...

Active, not recruiting
COPD
Other: Placebo
Biological: Biological: Solrikitug high dose

The study is being conducted to evaluate the effect of 3 dosing regimens of povorcitinib on pulmonary function

Active, not recruiting
Moderate to Severe Asthma
Drug: ICS-LABA
Other: placebo

The purpose of this study is to assess the long-term safety and to explore the efficacy of astegolimab in participants with chronic obstructive pulmo...

Active, not recruiting
Chronic Obstructive Pulmonary Disease
Drug: Astegolimab

The purpose of the study is to learn about how effective, safe, and tolerable the Clostridioides difficile (C. difficile) vaccine is in decreasing th...

Enrolling
Clostridoides Difficile Associated Disease
Biological: C.difficile vaccine
Other: Saline Placebo

This study is being done to learn about the safety and effects of a study medicine called berobenatide (bear-oh-BEN-uh-tide). The study will see if b...

Enrolling
Sleep Disorders
Overweight and/or Obesity
Other: Placebo
Drug: Berobenatide

The purpose of this clinical trial is to learn about the effects and safety of the study medicine PF-07275315 for the potential treatment of COPD. CO...

Enrolling
Moderate to Severe Chronic Obstructive Pulmonary Disease
Drug: Placebo
Drug: PF-07275315-dose 2

The purpose of this clinical study is to learn about the safety and effects of the study medicine (called tilrekimig) for the potential treatment of...

Enrolling
Asthma
Other: Placebo
Drug: tilrekimig

This study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and potential efficacy of ENV-294 in adults with mod...

Enrolling
Asthma
Drug: ENV-294
Drug: Placebo

Trial sponsors

Lilly logo
Pfizer logo
H
U
G
Incyte logo
M
Roche logo
E
V

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems